Lobe Sciences Ltd.: Lobe Sciences Enters into LOI with Core One Labs to Form a Joint Venture for the Clinical Development of Biosynthetic Psilocybin Lobe" or the " Company") is pleased to announce it has entered into a non-binding letter of intent dated April 27, 2021 (the " Agreement") with Core One Labs Inc. (CSE: COOL) (" Core One Labs") to pursue the formation of a joint venture involving the development, regulatory approval and marketing of biosynthetic psilocybin and other psychedelic compounds (the " Joint Venture"). "Lobe is pleased to pursue a partnership with Core One Labs, as we continue our business expansion efforts within the rapidly growing psilocybin and psychedelics space," said Philip Young, CEO of Lobe. "A joint venture is the logical next step for us as it has the potential to provide cGMP grade psilocybin for use in clinical studies we plan to initiate in the future."